BOD Election Application Frm 2016 v2

Transcription

1 BOD Election Application Frm 2016 v2 Submission Date Name :42:00 Connie Newman Board of Directors Please limit your message to 500 words. President-Elect (1) The American Medical Women's Association (AMWA) has been part of a long and hard journey to give women their rights in the medical profession. Although much has been achieved, AMWA is still needed today. AMWA has played an important role in advocating for women s health and reproductive rights, empowering women in medicine, including students and residents, and educating the medical community and the public about sex and gender based health and disease, gender inequality in medicine, human trafficking, healthy lifestyles, disease prevention, global health, and other issues connected to the well-being of women and their families. Recently AMWA has embarked on new arenas - depression and suicide, Alzheimer's disease, and gun violence to name a few. Importantly, AMWA has been an organization where physicians and students from diverse backgrounds and geographical areas can work together and learn from each other, creating lasting mentoring relationships. Although I am an experienced physician and scientist, I continue to learn from my AMWA colleagues, and am thankful that AMWA has enabled me to meet and network with so many wonderful and inspiring physicians and students. I have decided to seek the office of President-elect because of my commitment to AMWA, its mission, and members, and my interest in continuing the important work of AMWA. Personally, I feel a special connection to AMWA because one of my role models, Dr. Laura Morrow, my neighbor in my home town in New Jersey, was President of AMWA in the late 1960 s. I was in high school, and trying to enter the medical field at a time when most physicians were men. I have strong memories of what it was like then, not only for women entering medicine, but for women in general, and this motivates me to take an even greater role in advancing women in medicine, women s rights, and women s health. As President elect and President of AMWA I would strive to 1) continue the work outlined above, 2) seek out new areas where AMWA could be influential, 3) expand AMWA s reach through growing our membership and partnership with other medical and health promoting organizations, and 4) increase the visibility of AMWA as a leading medical organization that represents women in medicine and advances women's health. My qualifications for this important role include my work within AMWA on numerous committees including co-chair of the Fellowship Committee, Preventive Medicine Task Force, AMWA Editorial Committee, AWHS and recently the Membership Committee, my previous leadership roles in other organizations (both not for profit and private) and in the Endocrinology and Cardiovascular Health communities, my scientific and medical expertise and integrity, and perhaps most of all my dedication to AMWA, its members, and mission. Connie Newman, MD FACP FAMWA

2 A recent photo which is a headshot from the mid-chest to the top of the head. The photo should be taken against a white background. Publications Bibliography Publications in Peer reviewed Journals 1. New MI, Baum CJ (maiden name), and Levine LS. Nomograms relating aldosterone excretion to urinary sodium and potassium in the pediatric population: their application to the study of childhood hypertension. Am J Cardiol 1976; 37: Stevens VJ, Fantl WJ, Newman CB, Sims RV, Cerami A, and Peterson CM. Acetaldehyde adducts with hemoglobin. J Clin Invest 1981; 67: Newman CB, Levine LS, and New MI. Endocrine function in children with intrasellar and suprasellar neoplasms. Am J Dis Child 1981; 135: Newman CB, Wardlaw SL, Van Vugt DA, Ferrin M, and Frantz AG. Adrenocorticotropin immunoactivity in monkey hypophyseal portal blood. J Clin Endocrinol Metab 1984; 56: Cholst IN, Wardlaw SL, Newman CB, and Frantz AG. Prolactin response to breast stimulation in lactating women is not mediated by endogenous opiates. Am J Obstet Gynecol 1984; 150: Newman CB, Wardlaw SL, and Frantz AG. Suppression of basal and stress-induced prolactin release and stimulation of luteinizing hormone secretion by alpha-melanocyte-stimulating hormone. Life Sciences 1985; 36: Newman CB, Wardlaw SL, Stark RI, Daniel SS, and Frantz AG. Dopaminergic regulation of alpha-msh and N-acetyl-beta endorphin secretion in the fetal lamb. Endocrinology 1987; 120: Newman CB, Cosby H, Friesen HG, Feldman M, Cooper P, DeCrescito V, Pilon M, and Kleinberg DL. Evidence for a non-prolactin, non-growth hormone mammary mitogen in the human pituitary gland. Proc Natl Acad Sci (USA) 1987; 84:

3 9. Newman CB, Hurley AM and Kleinberg DL. Effect of CV in hyperprolactinemic patients intolerant of bromocriptine. Clin Endocrinol 1989; 31: Kleinberg DL, Ruan W, Catanese V, Newman CB and Feldman M. Non-lactogenic effects of growth hormone on growth and insulin-like growth factor I messenger ribonucleic acid of rat mammary gland. Endocrinol 1990; 126: Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook D, Malarkey WB, Jackson I, Vance ML, Thorner MO, Barkan A, Frohman LA, and Melmed S. Octreotide treatment of acromegaly: a multicenter double-blind placebo-controlled trial with long term efficacy studies. Ann Intern Med 1992; 117: Ruan W, Newman CB, and Kleinberg DL. Intact and amino - terminally shortened forms of insulin-like growth factor-i induce mammary gland differentiation and development. Proc Natl Acad Sci USA 1992; 89: Newman CB, Melmed S, Snyder PJ, Young WF, Boyajy LD, Levy R, Stewart WN, Klibanski A, Molitch ME, Gagel RF, Boyd AE, Sheeler L, Cook D, Malarkey WB, Jackson IMD, Vance ML, Thorner MO, Ho PJ, Jaffe CA, Frohman LA, and Kleinberg DL. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients-a clinical research center study. J Clin Endocrinol Metab 1995; 80: Wang C, Eyre DR, Clark R, Kleinberg D, Newman C, Iranmanesh A, Veldhuis J, Dudley RE, Berman N, Davidson T, Barstow TJ, Sinow R, Alexander G, Swerdloff RS. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men---a clinical research center study. J Clin Endocrinol Metab 1996; 81: Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998; 83: Newman CB, Palmer G, Silbershatz H, Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol 2003; 92: Newman CB, Tsai J, Szarek M, Luo D, Gibson E.Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 2006; 97: Leiter LA, Betteridge DJ, Chacra AR, Chait A, Ferannini E, Haffner SM, Kadovaki T, Tuomilehto J, Zimmet P, Newman CB, Hey-Hadavi J, Walkinshaw C on behalf of the AUDIT Steering Committee. AUDIT study. Evidence of global undertreatment of dylipidaemia in patients with type 2 diabetes mellitus. Brit J Diab Vasc Disease 2006; 6: Hitman GA, Colhoun H, Newman C, Szarek M, Betteridge DJ, Durrington PN, Fuller J, Livingstone S, Neil HAW, on behalf of the CARDS Investigators. Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Diab Med 2007; 24: Newman CB, Szarek M, Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Demicco DA, Auster S, Fuller JH; CARDS Investigators. The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Diab Vasc Dis Res 2008; 5: Charlton-Menys V, Betteridge DJ, Colhoun H, Fuller J, France M, Hitman GA, Livingstone SJ, Neil HA, Newman CB, Szarek M, DeMicco DA, Durrington PN. Targets of statin therapy: LDL cholesterol, non-hdl cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Clin Chem 2009; 55: Charlton-Menys V, Betteridge DJ, Colhoun H, Fuller J, France M, Hitman GA, Livingstone SJ, Neil HA, Newman CB, Szarek M, DeMicco DA, Durrington PN. Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2009; 52: Newman CB, Frisch KA, Rosenzweig B, Roubenoff R, Rey M, Kidder T, Kong Y, Pursnani A, Sedlis SP, Schwartzbard A, Kleinberg DL. Moderate doses of hgh improve lipids but not cardiovascular function in GH deficient adults with normal baseline cardiac function. J Clin Endocrinol Metab 2011; 96 (1): Cholesterol Treatment Trialists (CTT) Collaboration. [Writing Committee: Emberson J, Kearney P, Blackwell L, Newman C, Reith C, Bhala N, Holland L, Peto R, Keech T, Collins R, Simes J, Baigent C.] Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS ONE 2012; 7(1): e29849, doi: /journal.pone Newman CB, Carmichael JD, Kleinberg DL. Comparison of the effects of low dose versus high dose human growth hormone on body composition and lipids in adults with GH deficiency: a metaanalysis of placebo-controlled randomized trials Pituitary 18: Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgozoglu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, Marz W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN. Statin-associated muscle symptoms: impact on statin therapy. European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015; 36 (17): Clarke R, Newman C, Tomson J, Hin H, Kurien R, Cox J, Lay M, Sayer J, Hill M, Emberson J, Armitage J. Estimation of the optimum dose of vitamin D for disease prevention in older people: rationale, design and baseline characteristics of the BEST-D trial. Maturitas 2015; 80 (4): Newman CB and Tobert JA. Statin Intolerance: Reconciling clinical trials and clinical experience JAMA 313 (10): Tobert JA and Newman CB. Statin tolerability: In defence of placebo-controlled trials. Eur J Prev Cardiol 2015 Aug 28 pii: [Epub ahead of print] 30. Tobert, J.A.and Newman, C.B.. Statins and muscle symptoms (letter). Annals of Internal Medicine, 2015, in press. Posted at Newman CB, Tobert JA, Letter to the Editor: Comment on paper by Moriarty et al, Journal of Clinical Lipidology (2015), doi: /j.jacl degoma E, Ahmad ZS, O Brien E, Kindt I, Shrader P, Newman CB, Pokharel Y, Rader DJ, Moriarty PM, Gidding SS, Duell PB, Shapiro MD, Linton MF, Ballantyne CM, Duffy D, Baum SJ, Hemphill LC, Neal WA, Hudgins LC, Ahmed CD, Wilemon KA, Row MT, Knowles JW. LDL-C levels and treatment patterns among adults with heterozygous familial hypercholesterolemia in the United States: Data from the CASCADE-FH registry Circulation Cardiovascular Genetics (in press). 33. Tobert JA and Newman CB The nocebo effect in the context of statin intolerance J Clinical Lipidology (in press). 34. Hin H, Tomson J, Newman C, Kurien R, Lay M, Cox J, Sayer J, Hill M, Emberson J, Armitage J, Clarke R. for the BEST-D Trial Collaborative Group. Optimum dose of vitamin D for disease prevention in older people: BEST-D trial of vitamin D in primary care (Submitted for publication). Publications from the Cholesterol Treatment Trialists Collaboration 1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT)Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.. Lancet Oct 8; 366 (9493): Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet Jan 12; 371(9607): Cholesterol Treatment Trialists (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J,Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet Nov 13; 376 (9753): Collaborators (137) de Lemos J, Braunwald E, Blazing M, Murphy S, Downs JR, Gotto A, Clearfield M, Holdaas H, Gordon D, Davis B, Koren M, Dahlof B, Poulter N,Sever P, Knopp RH, Fellström B, Holdaas H, Jardine A, Schmieder R, Zannad F, Goldbourt U, Kaplinsky E, Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Fuller J, Neil A, Wanner C, Krane V, Sacks F, Moyé L, Pfeffer M, Hawkins CM, Braunwald E, Barter P, Keech A, Tavazzi L, Maggioni A, Marchioli R, Tognoni G, Franzosi MG, Maggioni A, Bloomfield H, Robins S, Collins R, Armitage J, Keech A, Parish S, Peto R, Sleight P, Pedersen TR, Ridker PM, Holman R, Meade T, Simes J, Keech A, MacMahon S, Marschner I, Tonkin A, Shaw J, Serruys PW, Nakamura H, Knatterud G,Furberg C, Byington R, Macfarlane P, Cobbe S, Ford I, Murphy M, Blauw GJ, Packard C, Shepherd J, Kjekshus J, Pedersen T, Wilhelmsen L,Braunwald E, Cannon C, Murphy S, Collins R, Armitage J, Bowman L, Parish S, Peto R, Sleight P, Baigent C, Baxter A, Collins R, Landray M, La Rosa J, Rossouw J, Probstfield J, Shepherd J, Cobbe S, Macfarlane P, Ford I, Flather M, Kastelein J, Newman C, Shear C, Tobert J, Varigos J, White H, Yusuf S, Mellies M, McGovern M, Barclay J, Belder R, Mitchel MY, Musliner T, Ansquer JC, Llewellyn BM, Bortolini M, Brandrup-Wognsen G,Bryzinski B, Olsson G, Pears J, DeMicco D, Baxter A, Baigent C, Barnes EH, Bhala N, Blackwell L, Buck G, Collins R, Emberson J, Herrington WG,Holland LE, Kearney PM, Keech A, Kirby A, Lewis DA, Marschner I, Pollicino C, Reith C, Simes J,

4 Sourjina T 4. Cholesterol Treatment Trialists' (CTT) Collaboration, Emberson JR, Kearney PM, Blackwell L, Newman C, Reith C, Bhala N, Holland L, Peto R, Keech A, Collins R, Simes J, Baigent C. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One. 2012;7(1):e doi: /journal.pone Epub 2012 Jan 19. Collaborators (125) de Lemos J, Braunwald E, Blazing M, Murphy S, Downs JR, Gotto A, Clearfield M, Holdaas H, Gordon D, Davis B, Koren M, Dahlof B, Poulter N,Sever P, Knopp RH, Fellström B, Holdaas H, Jardine A, Schmieder R, Zannad F, Goldbourt U, Kaplinsky E, Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Fuller J, Neil A, Wanner C, Krane V, Sacks F, Moyé L, Pfeffer M, Hawkins CM, Braunwald E, Kjekshus J, Wedel H, Wikstrand J,Tavazzi L, Maggioni A, Marchioli R, Tognoni G, Franzosi MG, Maggioni A, Collins R, Armitage J, Keech A, Parish S, Peto R, Sleight P, Pedersen TR,Ridker PM, Simes J, Keech A, MacMahon S, Marschner I, Tonkin A, Shaw J, Serruys PW, Nakamura H, Knatterud G, Furberg C, Byington R,Macfarlane P, Cobbe S, Ford I, Murphy M, Blauw GJ, Packard C, Shepherd J, Kjekshus J, Pedersen T, Wilhelmsen L, Braunwald E, Cannon C,Murphy S, Collins R, Armitage J, Bowman L, Parish S, Peto R, Sleight P, La Rosa J, Shepherd J, Cobbe S, Macfarlane P, Ford I, Flather M, Kastelein J, Newman C, Shear C, Tobert J, Varigos J, White H, Yusuf S, Baxter A, Baigent C, Barnes EH, Bhala N, Blackwell L, Buck G, Collins R, Emberson J,Herrington WG, Holland LE, Kearney PM, Keech A, Kirby A, Lewis DA, Marschner I, Reith C, Simes J, Mellies M, McGovern M, Barclay J, Belder R,Mitchell Y, Musliner T, Ansquer JC, Llewellyn M, Bortolini M, Bryzinski B, Olsson G, Pears J, DeMicco D. 5. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet Aug 11;380 (9841): Collaborators (139) de Lemos J, Braunwald E, Blazing M, Murphy S, Downs JR, Gotto A, Clearfield M, Holdaas H, Gordon D, Davis B, Koren M, Dahlof B, Poulter N,Sever P, Knopp RH, Fellström B, Holdaas H, Jardine A, Schmieder R, Zannad F, Goldbourt U, Kaplinsky E, Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Fuller J, Neil A, Wanner C, Krane V, Sacks F, Moyé L, Pfeffer M, Hawkins CM, Braunwald E, Kjekshus J, Wedel H, Wikstrand J,Barter P, Keech A, Tavazzi L, Maggioni A, Marchioli R, Tognoni G, Franzosi MG, Maggioni A, Bloomfield H, Robins S, Collins R, Armitage J, Keech A,Parish S, Peto R, Sleight P, Pedersen TR, Ridker PM, Holman R, Meade T, Simes J, Keech A, MacMahon S, Marschner I, Tonkin A, Shaw J, Serruys PW, Nakamura H, Knatterud G, Furberg C, Byington R, Macfarlane P, Cobbe S, Ford I, Murphy M, Blauw GJ, Packard C, Shepherd J, Kjekshus J,Pedersen T, Wilhelmsen L, Braunwald E, Cannon C, Murphy S, Collins R, Armitage J, Bowman L, Parish S, Peto R, Sleight P, Baigent C, Landray M,Collins R, La Rosa J, Rossouw J, Probstfield J, Shepherd J, Cobbe S, Macfarlane P, Ford I, Flather M, Kastelein J, Newman C, Shear C, Tobert J,Varigos J, White H, Yusuf S, Mellies M, McGovern M, Barclay J, Belder R, Mitchel Y, Musliner T, Ansquer JC, Llewellyn M, Bortolini M, Brandrup-Wognsen G, Bryzinski B, Olsson G, Pears J, DeMicco D, Baigent C, Barnes EH, Baxter A, Bhala N, Blackwell L, Buck G, Collins R, Emberson J,Herrington WG, Holland LE, Kearney PM, Keech A, Kirby A, Lewis DA, Marschner I, Pollicino C, Reith C, Simes J, Sourjina T 6. Cholesterol Treatment Trialists' (CTT) Collaboration, Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet Apr 11;385(9976): Collaborators (137) Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J,Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A, de Lemos J, Braunwald E, Blazing M, Murphy S, Downs JR, Gotto A, Clearfield M, Holdaas H, Gordon D, Davis B, Koren M, Dahlöf B, Poulter N, Sever P, Knopp RH, Fellström B, Holdaas H, Jardine A, Schmieder R,Zannad F, Goldbourt U, Kaplinsky E, Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Fuller J, Neil A, Wanner C, Krane V, Sacks F, Moyé L,Pfeffer M, Hawkins CM, Braunwald E, Kjekshus J, Wedel H, Wikstrand J, Barter P, Keech A, Tavazzi HF, Maggioni A, Tognoni RM, Franzosi MG,Maggioni A, Bloomfield H, Robins S, Collins R, Armitage J, Keech A, Parish S, Peto R, Sleight P, Pedersen TR, Ridker PM, Holman R, Meade T,Simes J, Keech A, MacMahon S, Marschner I, Tonkin A, Shaw J, Serruys PW, Nakamura H, Knatterud G, Furberg C, Byington R, Macfarlane P,Cobbe S, Ford I, Murphy M, Blauw GJ, Packard C, Shepherd J, Kjekshus J, Pedersen T, Wilhelmsen L, Braunwald E, Cannon C, Murphy S, Collins R, Armitage J, Bowman L, Parish S, Peto R, Sleight P, Baigent C, Landray M, Collins R, La Rosa J, Rossouw J, Probstfield J, Shepherd J, Cobbe S, Macfarlane P, Ford I, Flather M, Kastelein J, Newman C, Shear C, Tobert J, Varigos J, White H, Yusuf S, Barnes EH, Keech AC, Kirby A,Marschner IC, Simes J, Baigent C, Blackwell L, Collins R, Emberson J, Herrington WG, Holland LE, Mihaylova B, Reith C. Reviews, Books and Book Chapters 1. Kleinberg DL and Newman CB. The pituitary gland in primate development: evidence that prolactin is not essential In: Angeli, A., Bradlow, H.L., and Godlotti, L. (eds). Endocrinology of the Breast: Basic and Clinical Aspects. Annals of the New York Acad Sci 1986; Vol. 464, pages Kleinberg DL, Newman CB, and Feldman M. Role of the pituitary in mammary development. In: Melmed S and Robbins R (eds.) Molecular and Clinical Advances in Pituitary Disorders Blackwell Scientific Publications, Oxford, pp Newman CB and Kleinberg DL. Preoperative endocrinologic evaluation of the patient with a nonsecreting pituitary tumor. In: Cooper PR (ed.) Contemporary Diagnosis and Management of Pituitary Adenomas American Association of Neurologic Surgeons, Park Ridge, Illinois, pp Newman CB and Kleinberg DL. Acromegaly: how do you define cure? In: Cooper PR (ed.) Contemporary Diagnosis and Management of Pituitary Adenomas American Association of Neurological Surgeons, Park Ridge, Illinois, pp Weintraub HS, Field S, Hymes K, Newman CB and Kleinberg DL. The perioperative medical evaluation of neurosurgical patients. In: Tindall GT, Cooper PR, and Barrow DL (eds) The Practice of Neurosurgery Williams & Wilkins, Baltimore, MD, pp Newman CB. Long-term management of acromegaly. In: Clinical Endocrinology Update 1996, The Endocrine Society Press, Bethesda MD, pp Newman CB. Acromegaly. In: Bardin CW (ed.) Current therapy of Endocrinology and Metabolism. 1997, sixth edition. Mosby-Year Book, Inc., Philadelphia, PA., pp Newman CB and Kleinberg DL. Adult Growth Hormone Deficiency. The Endocrinologist 1998; 8: Newman CB. Medical therapy for acromegaly. In Advances in Pituitary Tumor Therapy. Endocrinology and Metabolism Clinics of North America. 1999; Volume Newman CB. Acromegaly. In Molitch M (ed.), Atlas of Clinical Endocrinology, Volume 4 Neuroendocrinology and Pituitary Disease Current Medicine Inc., Philadelphia PA. 11. Newman CB. Pharmacological treatment for sexual problems: The Benefits Outweigh the Risks. In Taverner B and McKee R (eds.) Taking Sides: Clashing Views in Human Sexuality, 12th ed., Mc-Graw Hll, Newman CB. Statin intolerance. Management of hyperlipidemia in the statin-intolerant patient. Meet the Professor Endocrine Case Management 2015-ebook; The Endocrine Society; pages Presentations Invited Seminars and Lectures : Diagnosis and Management of Acromegaly Evaluation of Growth Hormone Deficiency in Adults. Location: various medical centers in the U.S.

5 Management of Prolactinomas Location: AACE Annual Meeting 1998: Meet the Professor, Management of Acromegaly; Location: Endocrine Society Annual Meeting Introduction to Lipids and Lipoproteins Reducing Cardiovascular Risk in Patients with Diabetes Review of Cardiovascular Outcomes Trials of Statins Managing Dyslipidemia with Statins and Fibrates Familial Disorders of Lipid Metabolism Familial Hypercholesterolemia Hypertriglyceridemia: Etiology, Risks, and Treatment Strategies Management of Hyperlipidemia in the Statin Intolerant Patient Location: NY Harbor VA Hospital, Division of Endocrinology, Diabetes and Metabolism March 2015 Meet the Professor, Management of Hyperlipidemia in the Statin Intolerant Patient, Endocrine Society Annual Meeting, San Diego March 2015 Pathophysiology and Management of Obesity, Centennial Meeting of the American Medical Women s Association, Chicago Sept Meet the Professor, The Statin Intolerant Patient, Clinical Endocrinology Update Meeting, Miami February 5, 2016 Evidence for Prevention of Cardiovascular Disease in Type 2 Diabetes Mellitus: Review of Cardiovascular Outcomes Trials; Emirates Society of Endocrinology and Diabetes, Dubai February 6, 2016 Debate: In defense of no targeted goals: a debate about the American 2013 ACC/AHA Guideline and the European guideline; Emirates Society of Endocrinology and Diabetes, Dubai March 2016 Hot Topics in Hypercholesterolemia: Are Statins as Effective in Women as in Men; PCSK9 Inhibitors AMWA 101st Annual Meeting, Miami Sept 11, 2016 Statin Safety and Tolerability Endocrine Society Clinical Endocrinology Update, Seattle Abstracts Presented at National and International Meetings 1. Newman CB, Wardlaw SL, and Frantz AG. ACTH (CLIP) suppresses prolactin and stimulates LH secretion. Clin Res 1984; 32:271A. 2. Newman CB, Cosby H, Friesen H, Stampfer M, Monaco ME, and Kleinberg DL. Novel human pituitary factors stimulate growth of mammary cancer cells and normal mammary gland. Clin Res 1986; 34: 645A. 3. Newman CB, Boyett RL, and Kleinberg DL. CV : a long-acting dopamine agonist for the treatment of hyper-prolactinemia. September 13-16, 1987; 4th European Workshop on Pituitary Adenomas, Zurich, Switzerland. 4. Feldman M, Newman CB, and Kleinberg DL. Growth hormone is a more potent mammary mitogen than prolactin in vivo. Clin Res 1990; 38:343A. 5. Newman CB, Aronoff L, and Feldman M. Effects of growth hormone and prolactin on mammary development in hypophysectomized rhesus monkeys. 72nd Annual Meeting of the Endocrine Society, June 20-23, 1990, Atlanta, Georgia, Abstract The GH-Deficient Adult Study Group. GH therapy in adults with acquired GH deficiency: a double blind, randomized, placebo controlled one year intervention trial. 77th Annual Meeting of the Endocrine Society, June 14-17, 1995, Washington, DC, Abstract P Vance ML, Woodburn CJ, Putney S, Grous J, Lee HJ, Johnson OL, Kleinberg DL, Kidder T, Newman CB. Effects of sustained release growth hormone on serum GH, IGF-I, and IGFBP-3 concentrations in GH deficient adults. Second International Meeting of the Growth Hormone Research Society, November 13-16, 1996, London. 8. Growth Hormone Deficient Adult Study Group, Genentech Inc. Baseline abnormalities of body composition are more severe in adults with childhood-onset growth hormone deficiency. 79th Annual Meeting of the Endocrine Society, June 11-14, 1997, Minneapolis, MN, Abstract OR Newman C, Hopkinson C, Messig, M, Silbershatz H, Palmer G. Efficacy of atorvastatin in dyslipidemic patients with metabolic syndrome in the ACCESS study. 63rd Meeting of the American Diabetes Association, June 13-17, 2003, New Orleans, Abstract Newman C, Hopkinson C, Silbershatz H, Hey-Hadavi J, Palmer G. Comparison of the efficacy and safety of atorvastatin and simvastatin in dyslipidemic patients with metabolic syndrome in the ASSET study. 85th Annual Meeting of the Endocrine Society, June 19-22, 2003, Philadelphia, PA, Abstract Newman CB, Tsai J, Gibson E, Szarek M. Muscle-related adverse effects are comparable with atorvastatin versus placebo in 1660 patients. 15th International Symposium of Drugs Affecting Lipid Metabolism. October 24-28, 2004, Venice, Italy. 12. Hitman GA, Newman CB, Szarek M, Colhoun HM, Betteridge DJ, Durrington PN, Neil HAW, Livingstone S, Fuller JH on behalf of the CARDS Investigators. Effect of Atorvastatin on Stroke in Patients with Type 2 Diabetes: Factors Predicting the Risk of Stroke in the Collaborative Atorvastatin Diabetes Study (CARDS). 41st European Association for the Study of Diabetes Meeting, September 10-15, 2005, Athens, Greece. 13. Newman CB, Szarek M, Hitman GA, Colhoun HM, Betteridge DJ, Durrington PN, Neil HAW, Livingstone S, Fuller JH. Effect of Atorvastatin on Stroke in the Collaborative Atorvastatin Diabetes Study (CARDS): Factors Predictive of the Risk of Stroke. American Heart Association 2005 Scientific Sessions, November 13-16, Dallas Texas. 14. Hitman GA, Newman C, Szarek M, Colhoun HM, Betteridge DJ, Durriington PN, Neil A, Livingston SJ, Fuller JH. Stroke in Patients with Type 2 Diabetes: Further Analysis of the Collaborative Atorvastatin Diabetes Study (CARDS). 88th Annual Meeting of the Endocrine Society, June 24-27, 2006, Boston, Mass, Abstract P Newman C, Szarek M, DeMicco D, Hitman GA, Colhoun HM, Betteridge DJ, Durrington PN, Neil HA, Livingston SJ, Fuller JH. Safety of atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). 88th Annual Meeting of the Endocrine Society, June 24-27, 2006, Boston, Mass, Abstract P Frisch K, Newman CB, Rosenzweig B, Roubenoff R, Rey M, Kidder T, Kong Y, Schwartzbard A, Kleinberg, D. Are Currently Employed Growth Hormone Doses Sufficient to Provide Cardiovascular Benefits in Growth Hormone Deficient Adults? 91st Annual Meeting of the Endocrine Society, Ahmad Z, Newman C, O Brien E C, Shrader P, DeGoma EM, Ahmed CD, Moriarty PM, MacRae FL, Shapiro MD, Duell PB, Ballantyne CM, Neal WA, Duffy D, Hudgins LC, Hemphill L, Underberg, Watson KE, Gidding SS, Baum SJ, Wilemon K, Pickhardt D, Kindt I, Rader DJ, Roe MT, Knowles JW. Diagnosing Familial Hypercholesterolemia (FH) in the United States: Results from the CASCADE FH Patient Registry. 97th Annual Meeting of the Endocrine Society, San Diego, California, March 5-8, Newman CB, Clarke R, Hin H, Tomson J, Kurien R, Lay M, Sayer J, Hill M, Emberson J, Armitage J. Estimation of the Optimum Dose of Vitamin D for Older People: Results of the BEST-D Trial. 97th Annual Meeting of the Endocrine Society, San Diego, California, March 5-8, degoma E, Ahmad ZS, O Brien E, Kindt I, Shrader P, Newman CB, Pokharel Y, Rader DJ, Moriarty PM, Gidding SS, Duell PB, Shapiro MD, Linton MF, Ballantyne CM, Duffy D, Baum SJ, Hemphill LC, Neal WA, Hudgins LC, Ahmed CD, Wilemon KA, Row MT, Knowles JW. LDL-C levels and treatment patterns among adults with heterozygous familial hypercholesterolemia in the United States: Data from the CASCADE-FH registry. American Heart Association Scientific Sessions, Orlando, Florida, November 7-11, 2016.

6 Current type of practice, including title if applicable Community Involvement Activities Academic medicine: Adjunct Professor of Medicine, New York University School of Medicine, New York, NY Attending, Veterans Hospital New York, NY Boards and Community Organizations 2000 s Board of Directors, Grace Church School, Chair, Nominating Committee Board of Directors, NJ Wellesley Club Co-President, NJ Wellesley Club Leadership Council, Planned Parenthood Federation of America Founder, Wellesley Women in Medicine: a group of over 600 Wellesley alumnae in healthcare fields, and Wellesley pre-med students Board of Directors, NJ Family Planning League Board of Directors, Planned Parenthood of Greater Northern NJ Board of Directors, Planned Parenthood of Central and Greater Northern NJ Secretary Board of Directors, Planned Parenthood of Central and Greater Northern NJ Board of Directors, American Medical Women s Association Professional Activities Professional Societies Endocrine Society American College of Physicians Cholesterol Treatment Trialists Collaboration American Heart Association (AHA); Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Council American Medical Women s Association (AMWA) American Association of Clinical Endocrinologists (AACE) Obesity Society National Lipid Association (NLA) Member, Special Programs Committee, Endocrine Society Chair, Special Programs Committee, Endocrine Society Member, Scientific and Educational Programs Core Committee, Endocrine Society Member, Women s Leadership Committee, ATVB Council, AHA Member, Clinical Lipidology Committee, ATVB and Lifestyle Councils, AHA Membership Committee, NLA Graduate Medical Education Committee, NLA CME Committee, NLA Obesity Section Lead, Preventive Medicine Task Force, AMWA Co-Chair, Preventive Medicine Task Force, AMWA Co-Chair, Fellowship Committee, AMWA Co-Chair, AMWA Editorial Committee Co-Chair, Membership Committee, AMWA Co-Chair, American Women s Hospital Service Committee Lipid Committee, AACE Education Working Group, Obesity Society Consultant to FDA Endocrine and Metabolic Drugs (EMDAC) Advisory Committee Chair, AHA Writing Group, Scientific Statement: Statin Associated Adverse Events Editorial Boards Journal of Clinical Endocrinology and Metabolism Principal Clinical and Hospital Service Responsibilities Attending Physician Endocrinology and Diabetes Clinic, Veterans Administration Medical Center, New York, NY Attending Physician Endocrinology and Diabetes Service, Bellevue Hospital and Veterans Administration Medical Center, New York, NY Attending Physician, Endocrinology and Diabetes Clinic, Department of Veterans Affairs New York Harbor Healthcare Center Major Administrative Responsibilities Executive Director, Head of Cardiovascular Regulatory Affairs, Pfizer, Inc.

7 Teaching Experience Attending Physician Endocrinology and Diabetes Clinic, Veterans Administration Medical Center, New York, NY Attending Physician, Endocrinology and Diabetes Service, Bellevue Hospital and Veterans Administration Medical Center, New York, NY Endocrine Section Leader, Pathophysiology Course, New York University School of Medicine, New York, NY (8 hours per year) Attending Physician Endocrinology and Diabetes Clinic, Department of Veterans Affairs New York Harbor Healthcare Center, New York, NY; Review patients with Endocrine Fellows, lecture on various topics such as introduction to lipids, management of dyslipidemia, familial hypercholesterolemia, cardiovascular outcomes trials of statins, management of hypercholesterolemia (75 hours per year) Mentoring of Graduate Students, Residents, Post-Doctoral Fellows in Research I have mentored numerous Pre-medical and Medical students over the years as well as Residents and Endocrine Fellows Leadership Roles Current Level of involvement with AMWA Steering Committee, Collaborative Atorvastatin Diabetes Study (CARDS) , Head, Cardiovascular Regulatory Affairs, Pfizer, Inc , Chair of Planning Committee, Planned Parenthood Greater Northern NJ , Chair Board Development Committee, Planned Parenthood Central and Greater Northern NJ present Secretary, Board of Directors, Planned Parenthood of Central and Greater Northern NJ 2011-present, Founder and Leader, Wellesley Women in Medicine 2011-present, Steering Committee, BEST-D, a randomized trial comparing efficacy and safety of 2000 IU and 4000 IU vitamin D , Chair, Special Programs Committee, The Endocrine Society , Member, Women's Leadership Committee, ATVB Council, American Heart Association , Chair of AHA Writing Group for Scientific Statement on Statin Associated Adverse Events For AMWA- see below Lifetime Member Board of Directors 2015-present Obesity Section Lead, Preventive Medicine Task Force, AMWA Co-Chair, Preventive Medicine Task Force, AMWA Co-Chair, Fellowship Committee, AMWA Co-Chair, AMWA Editorial Committee Co-Chair, Membership Committee, AMWA Co-Chair, American Women s Hospital Service Committee